Skip to main content

Migraine Dosing Overview

For the preventive treatment of migraine in adults1

Recommended dose1a:

  • Month 1: Initial loading dose of 240 mg (2 consecutive SC 120 mg injections)
  • Subsequent months: 1 SC 120 mg injection per month

Treatment continues every month.

The loading dose of 240 mg in the Emgality-approved dosing regimen resulted in steady-state serum concentration after the first dose.1

See concentration graph

aThe Emgality Pen is 27 gauge x ½ inch.2

SC=subcutaneous.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

References

  1. Prescribing Information. Lilly USA, LLC.
  2. Data on File. Lilly USA, LCC. DOF-GZ-US-0060.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache